Karyopharm Therapeutics (KPTI) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Join SI Premium – FREE
Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.65), in-line with the analyst estimate of ($0.65). Revenue for the quarter came in at $0 , versus $30 thousand reported last year.
For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c
- Worthington Industries (WOR) Tops Q1 EPS by 7c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
